Sorrento Therapeutics Inc (SRNE)

1.80
NASDAQ : Health Care
Prev Close 1.80
Day Low/High 1.75 / 1.80
52 Wk Low/High 1.50 / 8.35
Avg Volume 625.00K
Exchange NASDAQ
Shares Outstanding 76.54M
Market Cap 137.77M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies

Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies

New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration

Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial In Patients With Radicular Pain For Its Lead Product, SP-102

- Pharmacokinetic data supports previous preclinical results, demonstrating an extended product residency time at the site of epidural injection

Sorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data From Head To Head Adhesion Study With Its Lead Product, ZTlido™

- ZTlido™ demonstrated superior adhesion as compared to the reference product in the EU

Short Interest Expands By 16.5% For SRNE

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 539,460 share increase in total short interest for Sorrento Therapeutics Inc , to 3,811,179, an increase of 16.49% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Promising Clinical Activity And Safety In Phase Ib Clinical Trial

- This is the second trial to demonstrate the safety and tolerability of our anti-CEA CAR-T hepatic artery infusions in heavily pre-treated, unresectable, chemotherapy refractory patients

Sorrento And Wildcat Announce Resolution

Sorrento Therapeutics Becomes Oversold (SRNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and...

Oversold Conditions For Sorrento Therapeutics (SRNE)

Oversold Conditions For Sorrento Therapeutics (SRNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Noteworthy Tuesday Option Activity: SRNE, RAIL, FEYE

Noteworthy Tuesday Option Activity: SRNE, RAIL, FEYE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sorrento Therapeutics Inc , where a total of 1,252 contracts have traded so far, representing approximately 125,200 underlying shares. That amounts to about 51.1% of SRNE's average daily trading volume over the past month of 244,825 shares.

Tax-Loss Selling Offers Stock-Picking Opportunities

Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.

Sorrento Therapeutics Enters Oversold Territory (SRNE)

Sorrento Therapeutics Enters Oversold Territory (SRNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Lack of Catalysts Keeps Analysts Away From Pfizer

Lack of Catalysts Keeps Analysts Away From Pfizer

Pfizer may not be the best investment in coming months, as doubts surface about the company's near-term prospects in the absence of M&A.

Noteworthy Monday Option Activity: SRNE, GNE, KBH

Noteworthy Monday Option Activity: SRNE, GNE, KBH

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sorrento Therapeutics Inc , where a total of 1,207 contracts have traded so far, representing approximately 120,700 underlying shares. That amounts to about 49.4% of SRNE's average daily trading volume over the past month of 244,400 shares.

TheStreet Quant Rating: D (Sell)